Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.
- Authors
- David, Sean P; Strong, David R; Leventhal, Adam M; Lancaster, Molly A; McGeary, John E; Munafò, Marcus R; Bergen, Andrew W; Swan, Gary E; Benowitz, Neal L; Tyndale, Rachel F; Conti, David V; Brown, Richard A; Lerman, Caryn; Niaura, Raymond
- Year
- 2013
- Journal
- Addiction (Abingdon, England)
- PMID
- 23941313
- DOI
- 10.1111/add.12325
- PMCID
- PMC3834197
AIMS: To evaluate the associations of treatment and an additive genetic efficacy score (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled into two randomized clinical trials of smoking cessation therapies. DESIGN: Double-blind pharmacogenetic efficacy trials randomizing participants to active or placebo bupropion. Study 1 also randomized participants to cognitive-behavioral smoking cessation treatment (CBT) or this treatment with CBT for depression. Study 2 provided standardized behavioural support. SETTING: Two hospital-affiliated clinics (study 1), and two university-affiliated clinics (study 2). PARTICIPANTS: A total of 792 self-identified white treatment-seeking smokers aged ≥18 years smoking ≥10 cigarettes per day over the last year. MEASUREMENTS: Age, gender, Fagerström Test for Nicotine Dependence, dopamine pathway genotypes (rs1800497 [ANKK1 E713K], rs4680 [COMT V158M], DRD4 exon 3 variable number of tandem repeats polymorphism [DRD4 VNTR], SLC6A3,3' VNTR) analyzed both separately and as part of an AGES, time to first lapse and point prevalence abstinence at end of treatment. FINDINGS: Significant associations of the AGES (hazard ratio [HR] = 1.10, 95% confidence interval [CI] = 1.06-1.14, P = 0.009) and of the DRD4 VNTR (HR = 1.29, 95% CI = 1.17-1.41, P = 0.0073) were observed with time to first lapse. A significant AGES by pharmacotherapy interaction was observed (β standard error = -0.18 [0.07], P = 0.016), such that AGES predicted risk for time to first lapse only for individuals randomized to placebo. CONCLUSIONS: A score based on functional polymorphisms relating to dopamine pathways appears to predict lapse to smoking following a quit attempt, and the association is mitigated in smokers using bupropion.
Displays the risk for lapse among smokers receiving bupropion or placebo as AGES scores increase. Grey regions represent 95% confidence limits.
LLM interpretation
This line graph illustrates the relationship between the Aggregate Genetic Efficacy Score (AGES) on the x-axis and the log Relative Hazard of smoking lapse on the y-axis. The placebo group (blue line) shows a positive correlation, where the risk of lapse increases as the AGES score increases, while the bupropion group (purple line) remains relatively flat. Grey shaded regions represent the 95% confidence limits for both groups.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | 2015 | 26142345 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A randomized trial of the effects of COMT inhibition on subjective response to alcohol: Moderation by baseline COMT activity and mediation of alcohol self-administration. | Schacht JP et al. | — | 2024 | → |
| Single Nucleotide Polymorphisms Within <i>DRD2, COMT, and DBH</i> and Smoking Cessation: A Systematic Review Considering Genetic Differences by Ancestry and Biological Sex. | Jones SK et al. | — | 2024 | → |
| The association of genetic polymorphisms within the dopaminergic system with nicotine dependence: A narrative review. | Yang J et al. | — | 2024 | → |
| Antidepressants for smoking cessation. | Hajizadeh A et al. | — | 2023 | → |
| A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations. | Prom-Wormley EC et al. | — | 2023 | → |
| Catechol-O-Methyltransferase Effects on Smoking: A Review and Proof of Concept of Sex-Sensitive Effects. | DeVito EE et al. | — | 2022 | → |
| Effects on time to lapse of switching menthol smokers to non-menthol cigarettes prior to a cessation attempt: a pilot study. | Kotlyar M et al. | — | 2021 | → |
| Multiethnic Prediction of Nicotine Biomarkers and Association With Nicotine Dependence. | Bergen AW et al. | — | 2021 | → |
| The Role of Pharmacogenetics in Smoking. | El-Boraie A et al. | — | 2021 | → |
| Translational Research in Nicotine Addiction. | Fisher ML et al. | — | 2021 | → |
| Antidepressants for smoking cessation. | Howes S et al. | — | 2020 | → |
| Dopamine genetic risk is related to food addiction and body mass through reduced reward-related ventral striatum activity. | Romer AL et al. | — | 2019 | → |
| Systematic Review of Polygenic Gene-Environment Interaction in Tobacco, Alcohol, and Cannabis Use. | Pasman JA et al. | — | 2019 | → |
| The VNTR 48 bp Polymorphism in the <i>DRD4</i> Gene Is Associated with Higher Tobacco Smoking in Male Mexican Mestizo Smokers with and without COPD. | Pérez-Rubio G et al. | — | 2019 | → |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | — | 2018 | → |
| Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. | Chen LS et al. | — | 2018 | → |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | — | 2018 | → |
| Environmental risks outweigh dopaminergic genetic risks for alcohol use and abuse from adolescence through early adulthood. | Coley RL et al. | — | 2017 | → |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | — | 2017 | → |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | — | 2017 | → |
| The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings. | Taranu A et al. | — | 2017 | → |
| Interactive effects of age and multi-gene profile on motor learning and sensorimotor adaptation. | Noohi F et al. | — | 2016 | → |
| Meta-analysis reveals significant association of 3'-UTR VNTR in SLC6A3 with smoking cessation in Caucasian populations. | Ma Y et al. | — | 2016 | → |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | — | 2015 | → |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | — | 2015 | → |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | — | 2015 | → |
| Are all placebo respondents non-smokers? | Enck P et al. | — | 2014 | → |
| Have the genetics of cannabis involvement gone to pot? | Agrawal A et al. | — | 2014 | → |
| Integrating genetics and social science: genetic risk scores. | Belsky DW et al. | — | 2014 | → |